GEORGE CLINICAL, EPS PARTNER ON BREAST CANCER STUDY IN ASIA PACIFIC

KUALA LUMPUR, June 28 (Bernama) -- George Clinical and EPS Corporation (EPS), a global contract research organisation (CRO) based in Japan are collaborating on a rare Japanese academia-led global study seeking to advance treatments for unmet needs in Asian populations.

In 2019, both companies formed a strategic partnership to help expand their operations across the Asia Pacific (APAC) region. Together, they have partnered on over 20 studies, mainly in oncology, kidney, metabolic and cardiovascular diseases therapeutic areas.

According to George Clinical in a statement, in this reciprocal strategic partnership, both companies come together to provide a seamless operating capability for clinical trials across the APAC region and globally.

Since September 2019, EPS and George Clinical have been involved in a major study for the National Cancer Center Hospital (NCCH), Japan on the clinical usefulness of a combination therapy in patients of any menopausal status with advanced or metastatic HR+/HER2- breast cancer.

A major objective of NCCH for conducting this study is to investigate a potential new treatment. The NCCH run PATHWAY trial is a clinical research collaboration with Pfizer Inc.

EPS is managing the PATHWAY study conducted in Japan, South Korea, Singapore and Taiwan. George Clinical is entirely responsible for study execution in Singapore and Taiwan with specific duties including full study conduct, regulatory, safety reporting and site monitoring.

George Clinical's strong expertise in regulatory, site knowledge and oncology expertise in the APAC region add value to the EPS strengths in Japan.

This PATHWAY study exemplifies the value of the strategic partnership of two highly experienced CROs who combine their services to ensure that a sponsor's study is conducted in the most efficient and effective manner to help bring new and advanced treatments to underserved populations.

NCCH believes the results of this PATHWAY study have a high impact for premenopausal breast cancer patients, for which a large percentage of patients exist in APAC with fewer treatment options.

Detailed efficacy and safety results were recently presented at the 2023 ASCO Annual Meeting.

-- BERNAMA